Alfatradiol: Can it help if my hair loss is linked to DHT?

When hair loss begins, many people immediately start looking for a cause. Among the most common—particularly in adults—is androgenetic alopecia, a form of patterned hair loss associated with a hormone called dihydrotestosterone (DHT). This form of thinning is closely tied to genetics, but understanding the hormonal mechanism behind it is key to evaluating a treatment like alfatradiol. So, if your hair loss is connected to DHT, can alfatradiol make a meaningful difference?

Dihydrotestosterone, usually abbreviated as DHT, derives from testosterone, one of the body's principal androgens. This transformation occurs via an enzyme called 5-alpha-reductase, which is present in many tissues, including the skin and scalp. DHT plays a developmental role during puberty—contributing to facial hair growth, a deeper voice and muscle mass—but it is also implicated in patterned hair loss later in life.

In people with a genetic sensitivity to DHT, the hormone binds to androgen receptors in scalp hair follicles, and those follicles progressively shrink in a process known as miniaturization. Miniaturization shortens the growth cycle and produces finer, weaker hairs, until follicles no longer produce visible hair. In men this typically shows as a receding hairline and thinning at the crown. In women, DHT-linked hair loss is more diffuse, often appearing as general thinning across the crown and a widening part.

Because DHT is central to this process, many treatments aim to reduce its production or interfere with its effect on hair follicles. Alfatradiol is one of the milder options in that group.

Alfatradiol: A Unique Molecule with Specific Action

Alfatradiol, also known as 17-alpha estradiol, is a stereoisomer of the naturally occurring estrogen 17-beta estradiol. Despite the chemical resemblance, alfatradiol is reported to have very weak estrogenic activity in reproductive tissue. That is the rationale for applying it to the scalp: the intent is a local effect rather than a systemic hormonal one. It is still a hormone. In Germany it is a pharmacy-only medicine sold without prescription; rules differ by country. It is authorised for androgenetic alopecia in Germany and is not FDA-approved in the United States.

What it does at the follicle has been studied mainly in the laboratory. Hoffmann and colleagues (Experimental Dermatology, 2002) report that 17α-estradiol reduces the amount of DHT formed by human hair follicles incubated with testosterone, while increasing the concentration of weaker steroids such as estrogens, and that it raises aromatase activity in intact follicles. That is a plausible route to changing the scalp's local hormonal environment — but a mechanism observed in cultured tissue is not the same as a demonstrated clinical effect, and the two should not be conflated.

What the clinical evidence actually shows

The controlled clinical evidence on topical alfatradiol is thin, and it comes from women.

The main randomised study is Blume-Peytavi and colleagues (Journal der Deutschen Dermatologischen Gesellschaft, 2007). 103 women with androgenetic alopecia were assigned either to 2% minoxidil twice daily for 12 months, or to 0.025% alfatradiol once daily for six months and then switched to minoxidil for months 7–12. Hair growth was measured with TrichoScan.

Six months of minoxidil produced a significant increase in cumulative hair thickness and absolute hair density. Over the same period, those measures "remained nearly unchanged" in the alfatradiol group. After the switch to minoxidil, thickness and density then rose significantly in that group too. The authors' conclusion was that minoxidil can increase hair density and thickness, whereas alfatradiol "results in deceleration or stabilization of hair loss." Both study medications were described as well tolerated.

There is also a small study of alfatradiol used together with minoxidil. Choe and colleagues (Annals of Dermatology, 2017) retrospectively evaluated 34 Korean women with female pattern hair loss who applied topical 0.025% 17α-estradiol with 3% minoxidil once daily for over six months; total hair count and hair caliber both increased. Its own title calls it noncomparative and retrospective — there was no alfatradiol-only arm and no minoxidil-only arm, so it cannot show what the alfatradiol contributed.

We could not find a published controlled trial of topical alfatradiol in men. Anyone reading the results above should keep in mind that they were measured in women.

Is Alfatradiol a DHT Blocker? A Closer Look at Mechanisms

It is tempting to call alfatradiol a DHT blocker, but that oversimplifies it. Finasteride and dutasteride are systemic 5-alpha-reductase inhibitors: they lower DHT throughout the body by blocking the enzyme that converts testosterone. They can be effective — a systematic review of 12 randomised trials in 3,927 men found finasteride superior to placebo on hair count and on patient and investigator assessment — and they are also associated with side effects including sexual problems, which some men report continued after stopping, and depression and suicidal thoughts (MHRA, May 2026).

Alfatradiol appears to work differently. Rather than suppressing DHT production body-wide, the laboratory evidence points to a local change in the follicle's steroid environment. Because it is applied topically and is not intended to change hormone levels elsewhere in the body, systemic exposure is expected to be lower — but "expected to be lower" is not the same as measured, and community members do report symptoms they attribute to systemic absorption.

One point for women specifically: oral finasteride and dutasteride are not indicated for women of childbearing potential, and both are contraindicated in pregnancy — they can cause abnormalities of the external genitalia in a male fetus, and crushed or broken finasteride tablets must not be handled by women who are or may become pregnant. That contraindication is a large part of why topical, locally acting options are discussed for women at all.

What role do products like Pantogar play in DHT-related hair loss?

People often ask whether supplements or "strengthening" shampoos affect DHT-related hair loss. One name that comes up is Pantogar, sold internationally as Pantovigar, in capsule and shampoo form. The capsules are an oral supplement whose stated composition is medicinal yeast, keratin, cystine, calcium pantothenate (vitamin B5), para-aminobenzoic acid and thiamine (vitamin B1). The manufacturer's rationale is nutritional support for the hair shaft; it is not a claim about hormones.

The important point is that Pantogar does not act on DHT, unlike alfatradiol or finasteride. It is positioned as general hair support, which makes it more relevant to conditions such as telogen effluvium (temporary shedding after stress, illness or nutritional deficiency) than to androgen-driven loss. Some people with androgenetic alopecia take a supplement alongside a DHT-directed treatment; that is a personal choice, not an evidence-based combination.

The same applies to the shampoo. As a rinse-off cosmetic, it has not been shown to inhibit DHT or to affect the underlying cause of androgenetic alopecia. Cosmetic ingredients can make hair feel thicker or look shinier without changing what is happening at the follicle. A review of vitamins and minerals in hair loss by Almohanna and colleagues (Dermatology and Therapy, 2019) concluded that supplementation is most defensible where a deficiency has actually been demonstrated — which is the honest frame for this whole product category. Supplements are not a substitute for a treatment aimed at the hormonal cause.

Weighing the Evidence: Can Alfatradiol Help With DHT-Linked Hair Loss?

On the published evidence, alfatradiol has not been shown to regrow hair, and the claim that it stabilises loss rests on a single randomised trial, in women, with no placebo group, in which the measured hair parameters did not improve and the comparator did better.

That does not prove it does nothing either. The trial authors credited alfatradiol with deceleration or stabilisation of hair loss, but without a placebo group this could not be tested. Both medications in that study were reported as well tolerated. But someone hoping for visible regrowth from alfatradiol alone is likely to be disappointed, and the evidence base is too small to say who responds and who does not.

Where it may fit is as one part of a broader routine — alongside a treatment with stronger evidence such as minoxidil — rather than as the main intervention. Talk to a doctor or pharmacist before starting, stopping or combining alfatradiol, and bring your full list of treatments including topicals. A clinician can also check whether your hair loss is in fact androgen-driven, which is the assumption this whole article rests on and is not something to diagnose from a photograph.

References

Blume-Peytavi, U., Kunte, C., Krisp, A., Garcia Bartels, N., Ellwanger, U., & Hoffmann, R. (2007). Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. Journal der Deutschen Dermatologischen Gesellschaft, 5(5), 391–395. https://pubmed.ncbi.nlm.nih.gov/17451383/

Choe, S. J., Lee, S., Choi, J., & Lee, W. S. (2017). Therapeutic efficacy of a combination therapy of topical 17α-estradiol and topical minoxidil on female pattern hair loss: a noncomparative, retrospective evaluation. Annals of Dermatology, 29(3), 276–282. https://pubmed.ncbi.nlm.nih.gov/28566902/

Hoffmann, R., Niiyama, S., Huth, A., Kissling, S., & Happle, R. (2002). 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Experimental Dermatology, 11(4), 376–380. https://pubmed.ncbi.nlm.nih.gov/12190948/

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

Mella, J. M., Perret, M. C., Manzotti, M., Catalano, H. N., & Guyatt, G. H. (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology, 146(10), 1141–1150. https://pubmed.ncbi.nlm.nih.gov/20956649/

Almohanna, H. M., Ahmed, A. A., Tsatalis, J. P., & Tosti, A. (2019). The role of vitamins and minerals in hair loss: a review. Dermatology and Therapy, 9(1), 51–70. https://pubmed.ncbi.nlm.nih.gov/30547302/